AACR Rationale for the Development of a Differentiated TROP2 ADC
2026 AACR Annual Meeting
A Novel Splicing- Targeted ADC Drives Immune Activation, Synergy with Checkpoint Inhibitors, and Enhanced Therapeutic Potential beyond Cytotoxicity
SITC November 2025
Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 ADC
2023 AACR Annual Meeting
Peak Bio, Inc introduces a novel immunostimulatory ADC payload targeting RNA splicing and demonstrates tumoricidal properties of a proof-of concept Her2 ADC
2021 AACR Annual Meeting
